Michael Morton Presents at EUROTOX 2018

Dr Michael Morton will be speaking at EUROTOX this September in Belgium.  On Tuesday September 4th at 16:30 in Hall 100 Mike will address ‘Cardiac safety: current state of the art’ chaired by Dr Mark Holbrook of VAST Pharma solutions and Ester Lovsin-Barle from Lonza.  Mike will present ‘Ion channel profiling of stem cell-derived cardiomyocytes: Useful reagents for automated patch-clamp?’

Drawing on research carried out last year and presented as a poster at Safety Pharmacology Society Annual Meeting 2017 in Berlin, Mike will discuss his experience with stem cell-derived cardiomyocytes. These cells were sourced from different manufacturers and tested by automated patch-clamp. Sodium and calcium channel currents were recorded, as were cardiac action potentials. The presentation will address whether these cells are a viable and useful reagent for ion channel screening.

EUROTOX is being held in Brussels this year and runs the 2nd to 5th of September 2018.  For more information see the EUROTOX website.  See the full programme here.

By |2018-08-23T12:05:35+00:00August 29th, 2018|Ion Channels, Events|Comments Off on Michael Morton Presents at EUROTOX 2018

About the Author:

Dr Michael Morton, PhD, Director and Cofounder, ApconiX, UK, an integrated toxicology and ion channel company that brings together a team of world-renowned nonclinical safety experts with over 400 years of drug discovery and development experience. Mike graduated from the University of Wolverhampton with a degree in Biomedical Sciences and then aspiration to work in hospital pathology. Having finished his Sandwich placement in Clinical Biochemistry at Sandwell Hospital and Mike subsequently gained a MSc in Clinical Biochemistry from the University of Manchester and carried out research into porphyrin metabolism. Moving to the University of Leeds, Mike completed his PhD in Pharmacology at researching adenosine receptor expression in the rat kidney . Mike was introduced to ion channels as a Post-Doc at Leeds and Yale University, patching with the likes of Fred Sigworth and Steve Hebert, then joined the Global Ion Channel Initiative at AstraZeneca. Mike worked at AstraZeneca for eight years before founding ApconiX with Professor Ruth Roberts and Dr Richard Knight. Mike has a serious passion for ion channels. And he’s very good at them . He is a serious scientist (with a serious sense of humour) who wants to make sure that every customer understands the consequences of the results he obtains and works with his colleagues to ensure a better decision is made on drug safety.